FDA Makes It Easier to Sell Some Unclassified Gadgets
Published Date: 6/5/2026
Notice
Summary
The FDA is planning to exempt some unclassified medical devices from the usual premarket notification rules, making it easier and faster for these devices to reach the market. This change affects manufacturers of certain medical devices and could save them time and money. The new guidance is effective starting June 5, 2026, but the FDA is still open to feedback from the public.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Some devices exempted from 510(k)
The FDA announced on June 5, 2026 that it intends to exempt certain unclassified medical devices from premarket notification (510(k)) requirements. During this time, FDA does not intend to enforce 510(k) requirements for those devices and does not expect manufacturers to submit 510(k)s, which may save manufacturers time and money.
Five product codes added to exemption list
The updated guidance (published June 5, 2026) adds five product codes that FDA assessed as meeting standards for exemption from premarket notification: LDK (Device, sensing, optical contour); MVV (Device, acupressure); MQZ (Prosthesis, nail); MIG (Strip, test isoniazid); and LXQ (Cup, eye). The update supersedes the June 2019 guidance and reflects FDA's current assessment that these device types meet exemption standards.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-18612, Medical Devices; Cardiovascular Devices; Classification of the Cardiovascular Machine Learning-Based Notification Software
The Food and Drug Administration (FDA) is classifying the cardiovascular machine learning-based notification software into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the cardiovascular machine learning- based notification software. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of the safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.
2026-18529, Agency Information Collection Activities; Proposed Collection; Comment Request; Medical Device Tracking
The FDA wants your thoughts on how they collect info to track medical devices. This affects companies that make or handle these devices and aims to keep things safe and clear. You’ve got until November 10, 2026, to share your comments—no cost, just your voice!
2026-18551, Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information; Aminobenzoic Acid (PABA) and Trolamine Salicylate
The Food and Drug Administration (FDA or Agency) is announcing the availability on its website of the final administrative order (final order) (OTC000008-1) titled "Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information; Aminobenzoic Acid (PABA) and Trolamine Salicylate." This final order amends "Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use" (Over- the-Counter (OTC) Monograph M020) to remove PABA and trolamine salicylate as sunscreen active ingredients. A sunscreen drug product containing PABA or trolamine salicylate is not generally recognized as safe and effective (GRASE).
Previous / Next Documents
Previous: 2026-11296, Notice of Determinations and Request for Comments Concerning Actions in Section 301 Investigations of Acts, Policies, and Practices of Various Economies Related to the Failure To Impose and Effectively Enforce a Prohibition on the Importation of Goods Produced With Forced Labor
The U.S. Trade Representative found that many countries aren’t stopping goods made with forced labor from entering the U.S. To fix this, they’re planning to add extra taxes (tariffs) on products from these countries, with rates between 10% and 12.5%. They’re also offering a special deal for some clothing imports and want your thoughts before finalizing these changes by early July 2026.
Next: 2026-11309, 60-Day Notice of Proposed Information Collection: Service Coordinators in Multifamily Housing
HUD wants to collect updated info from service coordinators who help people in multifamily housing. They’re asking for public feedback over the next 60 days before finalizing the forms and rules. This helps make sure funds are used right and keeps support services running smoothly, with no new costs for those involved.